News|Articles|October 14, 2025

FDA OKs Subcutaneous Guselkumab Regimen for Ulcerative Colitis: Daily Dose

Fact checked by: Grace Halsey

Your daily dose of the clinical news you may have missed.

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.


On September 22, 2025, we reported on the FDA approval of a subcutaneous (SC) induction regimen of guselkumab (Tremfya; Johnson & Johnson) for adults with moderately to severely active ulcerative colitis (UC).

The approval

With this decision, guselkumab becomes the first IL-23 inhibitor to offer both SC and intravenous (IV) induction options for the treatment of UC and Crohn disease (CD).

Approval was supported by results from the phase 3 ASTRO trial, which evaluated SC guselkumab in adults with UC who had inadequate response or intolerance to conventional and advanced therapies. Patients received 400 mg every 4 weeks for induction.

At week 12, 26% of patients in the guselkumab group achieved clinical remission compared with 7% in the placebo group (P<.001). Endoscopic improvement was observed in 36% of patients on guselkumab vs 12% on placebo (P<.001). Early separation from placebo occurred as early as week 2 and was sustained through week 24.

Week 24 data showed continued benefit with SC induction followed by maintenance therapy. Clinical remission rates were 34% for both 100 mg and 200 mg regimens compared with 10% for placebo (P<.001). Endoscopic improvement was reported in 39% and 44% of patients, respectively, vs 12% for placebo (P<.001). Efficacy was consistent with prior results from the QUASAR study that supported approval of intravenous (IV) induction in UC in 2024.

Click here for more details.


Newsletter

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.


Latest CME